Katherine L Musliner1,2, Preben B Mortensen1,2,3, John J McGrath2,4,5, Nis P Suppli1,6, David M Hougaard1,7, Jonas Bybjerg-Grauholm1,7, Marie Bækvad-Hansen1,7, Ole Andreassen8,9, Carsten B Pedersen1,2,3, Marianne G Pedersen1,2,3, Ole Mors1,10, Merete Nordentoft1,6, Anders D Børglum1,11, Thomas Werge1,12,13, Esben Agerbo2,3. 1. iPSYCH, The Lundbeck Foundation Initiative for Integrated Psychiatric Research, Denmark. 2. National Centre for Register-based Research, Department of Economics and Business Economics, Aarhus University, Aarhus, Denmark. 3. Center for Integrated Register-based Research at Aarhus University, Aarhus, Denmark. 4. Queensland Brain Institute, The University of Queensland, St Lucia, Queensland, Australia. 5. Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Wacol, Queensland, Australia. 6. Mental Health Centre Copenhagen, Capital Region of Denmark, Copenhagen University Hospital, Copenhagen, Denmark. 7. Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark. 8. The Norwegian Centre for Mental Disorders Research, Division of Mental Health and Addiction, University of Oslo, Oslo, Norway. 9. Oslo University Hospital, Oslo, Norway. 10. Psychosis Research Unit, Aarhus University Hospital, Risskov, Denmark. 11. Centre for Integrative Sequencing, Department of Biomedicine and iSEQ, Aarhus University, Aarhus, Denmark. 12. Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. 13. Institute of Biological Psychiatry, Copenhagen Mental Health Services, Copenhagen, Denmark.
Abstract
Importance: Although the usefulness of polygenic risk scores as a measure of genetic liability for major depression (MD) has been established, their association with depression in the general population remains relatively unexplored. Objective: To evaluate whether polygenic risk scores for MD, bipolar disorder (BD), and schizophrenia (SZ) are associated with depression in the general population and explore whether these polygenic liabilities are associated with heterogeneity in terms of age at onset and severity at the initial depression diagnosis. Design, Setting, and Participants: Participants were drawn from the Danish iPSYCH2012 case-cohort study, a representative sample drawn from the population of Denmark born between May 1, 1981, and December 31, 2005. The hazard of depression was estimated using Cox regressions modified to accommodate the case-cohort design. Case-only analyses were conducted using linear and multinomial regressions. The data analysis was conducted from February 2017 to June 2018. Exposures: Polygenic risk scores for MD, BD, and SZ trained using the most recent genome-wide association study results from the Psychiatric Genomics Consortium. Main Outcomes and Measures: The main outcome was first depressive episode (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] code F32) treated in hospital-based psychiatric care. Severity at the initial diagnosis was measured using the ICD-10 code severity specifications (mild, moderate, severe without psychosis, and severe with psychosis) and treatment setting (inpatient, outpatient, and emergency). Results: Of 34 573 participants aged 10 to 31 years at censoring, 68% of those with depression were female compared with 48.9% of participants without depression. Each SD increase in polygenic liability for MD, BD, and SZ was associated with 30% (hazard ratio [HR], 1.30; 95% CI, 1.27-1.33), 5% (HR, 1.05; 95% CI, 1.02-1.07), and 12% (HR, 1.12; 95% CI, 1.09-1.15) increases in the hazard of depression, respectively. Among cases, a higher polygenic liability for BD was associated with earlier depression onset (β = -.07; SE = .02; P = .002). Conclusions and Relevance: Polygenic liability for MD is associated with first depression in the general population, which supports the idea that these scores tap into an underlying liability for developing the disorder. The fact that polygenic risk for BD and polygenic risk for SZ also were associated with depression is consistent with prior evidence that these disorders share some common genetic overlap. Variations in polygenic liability may contribute slightly to heterogeneity in clinical presentation, but these associations appear minimal.
Importance: Although the usefulness of polygenic risk scores as a measure of genetic liability for major depression (MD) has been established, their association with depression in the general population remains relatively unexplored. Objective: To evaluate whether polygenic risk scores for MD, bipolar disorder (BD), and schizophrenia (SZ) are associated with depression in the general population and explore whether these polygenic liabilities are associated with heterogeneity in terms of age at onset and severity at the initial depression diagnosis. Design, Setting, and Participants: Participants were drawn from the Danish iPSYCH2012 case-cohort study, a representative sample drawn from the population of Denmark born between May 1, 1981, and December 31, 2005. The hazard of depression was estimated using Cox regressions modified to accommodate the case-cohort design. Case-only analyses were conducted using linear and multinomial regressions. The data analysis was conducted from February 2017 to June 2018. Exposures: Polygenic risk scores for MD, BD, and SZ trained using the most recent genome-wide association study results from the Psychiatric Genomics Consortium. Main Outcomes and Measures: The main outcome was first depressive episode (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision [ICD-10] code F32) treated in hospital-based psychiatric care. Severity at the initial diagnosis was measured using the ICD-10 code severity specifications (mild, moderate, severe without psychosis, and severe with psychosis) and treatment setting (inpatient, outpatient, and emergency). Results: Of 34 573 participants aged 10 to 31 years at censoring, 68% of those with depression were female compared with 48.9% of participants without depression. Each SD increase in polygenic liability for MD, BD, and SZ was associated with 30% (hazard ratio [HR], 1.30; 95% CI, 1.27-1.33), 5% (HR, 1.05; 95% CI, 1.02-1.07), and 12% (HR, 1.12; 95% CI, 1.09-1.15) increases in the hazard of depression, respectively. Among cases, a higher polygenic liability for BD was associated with earlier depression onset (β = -.07; SE = .02; P = .002). Conclusions and Relevance: Polygenic liability for MD is associated with first depression in the general population, which supports the idea that these scores tap into an underlying liability for developing the disorder. The fact that polygenic risk for BD and polygenic risk for SZ also were associated with depression is consistent with prior evidence that these disorders share some common genetic overlap. Variations in polygenic liability may contribute slightly to heterogeneity in clinical presentation, but these associations appear minimal.
Authors: Morgan E Levine; Eileen M Crimmins; Carol A Prescott; Drystan Phillips; Thalida E Arpawong; Jinkook Lee Journal: Biodemography Soc Biol Date: 2014
Authors: C B Pedersen; J Bybjerg-Grauholm; M G Pedersen; J Grove; E Agerbo; M Bækvad-Hansen; J B Poulsen; C S Hansen; J J McGrath; T D Als; J I Goldstein; B M Neale; M J Daly; D M Hougaard; O Mors; M Nordentoft; A D Børglum; T Werge; P B Mortensen Journal: Mol Psychiatry Date: 2017-09-19 Impact factor: 15.992
Authors: Takahiro Soda; Declan M McLoughlin; Scott R Clark; Leif Oltedal; Ute Kessler; Jan Haavik; Chad Bousman; Daniel J Smith; Miquel Bioque; Caitlin C Clements; Colleen Loo; Fidel Vila-Rodriguez; Alessandra Minelli; Brian J Mickey; Roumen Milev; Anna R Docherty; Julie Langan Martin; Eric D Achtyes; Volker Arolt; Ronny Redlich; Udo Dannlowski; Narcis Cardoner; Emily Clare; Nick Craddock; Arianna Di Florio; Monika Dmitrzak-Weglarz; Liz Forty; Katherine Gordon-Smith; Mustafa Husain; Wendy M Ingram; Lisa Jones; Ian Jones; Mario Juruena; George Kirov; Mikael Landén; Daniel J Müller; Axel Nordensköld; Erik Pålsson; Meethu Paul; Agnieszka Permoda; Bartlomiej Pliszka; Jamie Rea; Klaus O Schubert; Joshua A Sonnen; Virginia Soria; Will Stageman; Akihiro Takamiya; Mikel Urretavizacaya; Stuart Watson; Maxim Zavorotny; Allan H Young; Eduard Vieta; Janusz K Rybakowski; Massimo Gennarelli; Peter P Zandi; Patrick F Sullivan; Bernhard T Baune Journal: Eur Arch Psychiatry Clin Neurosci Date: 2019-12-04 Impact factor: 5.270
Authors: Nikolaos Koutsouleris; Michelle Worthington; Dominic B Dwyer; Lana Kambeitz-Ilankovic; Rachele Sanfelici; Paolo Fusar-Poli; Marlene Rosen; Stephan Ruhrmann; Alan Anticevic; Jean Addington; Diana O Perkins; Carrie E Bearden; Barbara A Cornblatt; Kristin S Cadenhead; Daniel H Mathalon; Thomas McGlashan; Larry Seidman; Ming Tsuang; Elaine F Walker; Scott W Woods; Peter Falkai; Rebekka Lencer; Alessandro Bertolino; Joseph Kambeitz; Frauke Schultze-Lutter; Eva Meisenzahl; Raimo K R Salokangas; Jarmo Hietala; Paolo Brambilla; Rachel Upthegrove; Stefan Borgwardt; Stephen Wood; Raquel E Gur; Philip McGuire; Tyrone D Cannon Journal: Biol Psychiatry Date: 2021-07-06 Impact factor: 13.382
Authors: Rachele Sanfelici; Anne Ruef; Linda A Antonucci; Nora Penzel; Aristeidis Sotiras; Mark Sen Dong; Maria Urquijo-Castro; Julian Wenzel; Lana Kambeitz-Ilankovic; Meike D Hettwer; Stephan Ruhrmann; Katharine Chisholm; Anita Riecher-Rössler; Peter Falkai; Christos Pantelis; Raimo K R Salokangas; Rebekka Lencer; Alessandro Bertolino; Joseph Kambeitz; Eva Meisenzahl; Stefan Borgwardt; Paolo Brambilla; Stephen J Wood; Rachel Upthegrove; Frauke Schultze-Lutter; Nikolaos Koutsouleris; Dominic B Dwyer Journal: Cereb Cortex Date: 2022-04-05 Impact factor: 4.861
Authors: Luiza Kvitko Axelrud; João Ricardo Sato; Marcos Leite Santoro; Fernanda Talarico; Daniel Samuel Pine; Luis Augusto Rohde; Andre Zugman; Edson Amaro Junior; Rodrigo Affonseca Bressan; Rodrigo Grassi-Oliveira; Pedro Mario Pan; Maurício Scopel Hoffmann; Andre Rafael Simioni; Salvador Martin Guinjoan; Hakon Hakonarson; Elisa Brietzke; Ary Gadelha; Renata Pellegrino da Silva; Marcelo Queiroz Hoexter; Euripedes Constantino Miguel; Sintia Iole Belangero; Giovanni Abrahão Salum Journal: Neurobiol Aging Date: 2019-07-06 Impact factor: 4.673
Authors: Rachel L Kember; Alison K Merikangas; Shefali S Verma; Anurag Verma; Renae Judy; Scott M Damrauer; Marylyn D Ritchie; Daniel J Rader; Maja Bućan Journal: Biol Psychiatry Date: 2020-07-06 Impact factor: 13.382